T
12.43
0.34 (2.81%)
| Previous Close | 12.09 |
| Open | 12.15 |
| Volume | 1,734,250 |
| Avg. Volume (3M) | 2,082,816 |
| Market Cap | 839,888,960 |
| Price / Earnings (Forward) | 1.11 |
| Price / Sales | 0.850 |
| Price / Book | 6.48 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -18.71% |
| Operating Margin (TTM) | -14.71% |
| Diluted EPS (TTM) | -2.79 |
| Quarterly Revenue Growth (YOY) | 22.30% |
| Total Debt/Equity (MRQ) | 320.75% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | 13.94 M |
| Levered Free Cash Flow (TTM) | 67.48 M |
| Return on Assets (TTM) | -6.17% |
| Return on Equity (TTM) | -92.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Tandem Diabetes Care, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.4
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.40 |
|
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 0.95% |
| % Held by Institutions | 110.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sessa Capital Im, L.P. | 30 Jun 2025 | 5,000,000 |
| Gw&K Investment Management, Llc | 30 Jun 2025 | 2,890,130 |
| Hood River Capital Management Llc | 30 Jun 2025 | 2,564,978 |
| Paradice Investment Management Llc | 30 Jun 2025 | 1,767,179 |
| Ophir Asset Management Pty Ltd | 30 Jun 2025 | 1,464,956 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (Barclays, 310.30%) | Buy |
| Median | 17.00 (36.77%) | |
| Low | 11.00 (Citigroup, -11.50%) | Hold |
| Average | 21.00 (68.95%) | |
| Total | 4 Buy, 5 Hold | |
| Avg. Price @ Call | 11.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 08 Sep 2025 | 22.00 (76.99%) | Buy | 12.50 |
| Citigroup | 21 Aug 2025 | 11.00 (-11.50%) | Hold | 11.05 |
| 12 Aug 2025 | 10.35 (-16.73%) | Hold | 11.11 | |
| Lake Street | 11 Aug 2025 | 12.00 (-3.46%) | Hold | 10.12 |
| Barclays | 08 Aug 2025 | 51.00 (310.30%) | Buy | 11.23 |
| Canaccord Genuity | 07 Aug 2025 | 24.00 (93.08%) | Buy | 11.52 |
| Piper Sandler | 07 Aug 2025 | 14.00 (12.63%) | Hold | 11.52 |
| RBC Capital | 07 Aug 2025 | 25.00 (101.13%) | Buy | 11.52 |
| UBS | 07 Aug 2025 | 17.00 (36.77%) | Hold | 11.52 |
| Wells Fargo | 07 Aug 2025 | 13.00 (4.59%) | Hold | 11.52 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARPENTER RICK | - | 12.27 | -207 | -2,540 |
| NOVARA MARK DAVID | - | 12.27 | -3,866 | -47,436 |
| Aggregate Net Quantity | -4,073 | |||
| Aggregate Net Value ($) | -49,976 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.27 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NOVARA MARK DAVID | Officer | 15 Sep 2025 | Disposed (-) | 3,866 | 12.27 | 47,436 |
| NOVARA MARK DAVID | Officer | 15 Sep 2025 | Option execute | 7,415 | - | - |
| CARPENTER RICK | Officer | 15 Sep 2025 | Disposed (-) | 207 | 12.27 | 2,540 |
| CARPENTER RICK | Officer | 15 Sep 2025 | Option execute | 406 | - | - |
| Date | Type | Details |
|---|---|---|
| 16 Sep 2025 | Announcement | Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels |
| 04 Sep 2025 | Announcement | Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones |
| 07 Aug 2025 | Announcement | Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps |
| 31 Jul 2025 | Announcement | Tandem Diabetes Care Announces Upcoming Conference Participation |
| 15 Jul 2025 | Announcement | Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity |
| 01 Jul 2025 | Announcement | Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 |
| 20 Jun 2025 | Announcement | Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |